接受免疫抑制治疗的风湿病患儿接种水痘疫苗可产生体液和细胞免疫应答
本研究评估幼年特发性关节炎、幼年皮肌炎或幼年硬皮病患儿接种减毒活水痘-带状疱疹病毒疫苗后的体液和细胞应答,并与健康对照比较。49例患者和18例健康对照在接种前、接种后4-6周及一年采集血样。结果显示患者抗体应答与对照相似(p=0.139),免疫抑制药物不影响应答(p=0.203),接种后VZV特异性T细胞增加(p=0.043),未报告疾病复发。
要点
- 患儿接种水痘疫苗后抗体应答与健康对照相似(p=0.139)。
- 使用免疫抑制药物不影响疫苗抗体应答(p=0.203)。
- 接种后VZV特异性T细胞增加(p=0.043),未报告疾病复发。
核心结论
- 儿童风湿病患者对水痘疫苗接种的体液应答与健康对照相似。
- 患者通常能够产生VZV特异性细胞应答。
研究设计与样本
- 研究纳入49例患者(39例幼年特发性关节炎、5例幼年皮肌炎、5例幼年硬皮病)和18例健康对照,在接种前、接种后4-6周及一年采集血样。
- 所有患者使用甲氨蝶呤,16例同时使用糖皮质激素,3例使用生物制剂。
- 通过ELISA和多联免疫assay检测VZV特异性抗体浓度,IFN-γ ELISpot检测VZV特异性T细胞应答,Luminex assay检测VZV刺激后细胞因子产生。
主要发现
- 患者与对照的疫苗抗体应答相似(p=0.139)。
- 免疫抑制药物的使用不影响应答(p=0.203)。
- 第二次接种(n=21)提高VZV特异性抗体浓度(p=0.02)。
- 接种后VZV特异性T细胞增加(p=0.043),细胞因子谱提示VZV特异性Th1和细胞毒性T细胞应答。
- 接种后未报告疾病复发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess humoral and cellular responses to live-attenuated varicella zoster virus (VZV) vaccination of patients with juvenile idiopathic arthritis (JIA), juvenile dermatomyositis (JDM) or juvenile scleroderma (JScle) compared to those of healthy controls (HC). METHODS: Before, 4-6weeks and one year after VZV vaccination, blood samples of patients and HC were collected. VZV-specific antibody concentrations were measured by ELISA and multiplex immune-assay. IFN-γ ELISpot assays were performed to assess VZV-specific T-cell responses. Cytokine production upon VZV stimulation were measured with a Luminex-assay. RESULTS: 49 patients (39 JIA, 5 JDM, 5 JScle) and 18 HC were included. All patients used methotrexate (MTX), 16 also used corticosteroids, 3 patients used biologics. No disease flares were reported after vaccination. Antibody response to the vaccine was similar in patients and controls (p=0.139). Use of immunosuppressive drugs did not affect the response (p=0.203). A second vaccination (n=21) increased VZV-specific antibody concentrations (p=0.02). VZV-specific T-cells increased after vaccination (p=0.043), with a cytokine profile suggesting a VZV-specific Th1 and cytotoxic T-cell response. CONCLUSION: The humoral response to VZV vaccination in patients with pediatric rheumatic diseases (PRD) is similar to that of HC. Generally, patients are able to mount a VZV-specific cellular response. This study has been registered in the Brazilian Clinical Trials Registry under number U1111-1189-9837.
引用
- Groot N, Pileggi G, Sandoval CB, et al. Varicella vaccination elicits a humoral and cellular response in children with rheumatic diseases using immune suppressive treatment. Vaccine. 2017. PMID: 28412076. doi:10.1016/j.vaccine.2017.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。